18F-FDG PET/CT代谢参数在NK/T细胞淋巴瘤预后价值的评估

doi:10.16150/j.1671-2870.2019.03.020

诊断学理论与实践 ›› 2019, Vol. 18 ›› Issue (03): 349-352.doi: 10.16150/j.1671-2870.2019.03.020

¹⁸F-FDG PET/CT代谢参数在NK/T细胞淋巴瘤预后价值的评估

沈文斌, 郭睿, 李彪()

上海交通大学医学院附属瑞金医院核医学科,上海 200025

收稿日期:2019-03-25 出版日期:2019-06-25 发布日期:2019-06-25
通讯作者: 李彪 E-mail:lb10363@rjh.com.cn
基金资助:
上海市重点专科建设项目

Prognostic value of ¹⁸F-FDG PET/CT metabolic parameters in NK/T cell lymphoma

SHEN Wenbin, GUO Rui, LI Biao()

Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2019-03-25 Online:2019-06-25 Published:2019-06-25
Contact: LI Biao E-mail:lb10363@rjh.com.cn

摘要/Abstract

摘要：

目的： 评估¹⁸F-FDG PET/CT检查的代谢参数[最大标准摄取值（maximum standardized uptake value,SUVmax）、肿瘤代谢体积（metabolic tumour volume,MTV）、肿瘤糖酵解负荷（total lesion glycolysis,TLG）]在自然杀伤（natural killer,NK）/T细胞淋巴瘤患者预后评估中的价值。方法： 回顾性分析27例经病理确诊的NK/T细胞淋巴瘤患者,患者均在治疗前进行了基线PET/CT检查,随后接受相同方案治疗,中位随访23个月,每例患者在随访期间至少进行了一次治疗中或治疗末期的PET/CT评估。统计所有患者的PET/CT代谢参数SUVmax、MTV、TLG以无进展生存（progression-free survival,PFS）期及总生存（overall survival,OS）期为评价指标,进行Kaplan-Meier生存曲线分析。结果： 27例NK/T细胞淋巴瘤患者中5例出现了疾病进展,其中3例死亡。PET/CT检查参数中,MTV、TLG是NK/T细胞淋巴瘤患者PFS的预测因子,MTV>16.97 cm³及TLG>74.70×10³预示疾病进展（MTV,P=0.013;TLG,P=0.029）,SUVmax则无法预测PFS（P=0.661）。然而,这3项代谢参数均无法预测患者的OS（SUVmax,P=0.293;MTV,P=0.198;TLG,P=0.108）。结论： ¹⁸F-FDG PET/CT代谢参数MTV、TLG可能有助于预测NK/T细胞淋巴瘤患者的PFS,而无法预测其OS;SUVmax则在NK/T细胞淋巴瘤预后评估中的价值不大。

关键词: 自然杀伤/T细胞淋巴瘤, ¹⁸F-FDG PET/CT, 预后价值

Abstract:

Objective: To analyze the prognostic value of metabolic parameters of ¹⁸F-FDG PET/CT examination [maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG)] in patients with natural killer (NK)/T-cell lymphoma. Methods: A retrospective analysis of 27 patients with pathologically confirmed NK/T-cell lymphoma who underwent baseline PET/CT before treatment and then receiving the same treatment was performed. The median follow-up was 23 months. Each patient had at least one PET/CT re-assessment during follow-up or at the end of treatment. The PET/CT metabolic parameters SUVmax, MTV and TLG were analyzed statistically. The Kaplan-Meier survival curve was used to assess the progression-free survival (PFS) and overall survival (OS). Results: Of the 27 patients, 5 had disease progression and 3 of them died. Among the PET/CT parameters, MTV and TLG were the predictors of PFS in patients with NK/T-cell lymphoma (MTV: P=0.013, TLG: P=0.029), while SUVmax could not predict PFS (P=0.661). However, none of the 3 metabolic parameters could predict the OS (SUVmax, P=0.293; MTV, P=0.198; TLG, P=0.108). Conclusions: ¹⁸F-FDG PET/CT metabolic parameters MTV, TLG may help predicting PFS in patients with NK/T-cell lymphoma, but cannot predict OS; SUVmax is of little value in prognostic prediction of NK/T-cell lymphoma

Key words: Natural killer/T-cell lymphoma, ¹⁸F-FDG PET/CT, Prognostic value

中图分类号:

R733.1

沈文斌, 郭睿, 李彪. ¹⁸F-FDG PET/CT代谢参数在NK/T细胞淋巴瘤预后价值的评估[J]. 诊断学理论与实践, 2019, 18(03): 349-352.

SHEN Wenbin, GUO Rui, LI Biao. Prognostic value of ¹⁸F-FDG PET/CT metabolic parameters in NK/T cell lymphoma[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(03): 349-352.

图/表 2

参考文献 17

[1]	Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years[J]. Ann Oncol, 2005, 16(2):206-214. pmid: 15668271
[2]	Fujita M, Yamashiro K, Ichinohasama R, et al. The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists[J]. Pathol Int, 2000, 50(9):696-702. doi: 10.1046/j.1440-1827.2000.01108.x URL
[3]	Chen CY, Yao M, Tang JL, et al. Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to T-cell lymphoma[J]. Ann Oncol, 2004, 15(7):1091-1096. pmid: 15205204
[4]	Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study[J]. J Clin Oncol, 2006, 24(4):612-618. doi: 10.1200/JCO.2005.04.1384 URL
[5]	Suzuki R, Takeuchi K, Ohshima K, et al. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues[J]. Hematol Oncol, 2008, 26(2):66-72. doi: 10.1002/hon.847 URL
[6]	Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type[J]. Blood, 2018, 131(23):2528-2540. doi: 10.1182/blood-2017-12-791418 pmid: 29602763
[7]	Tse E, Kwong YL. Practical management of natural killer/T-cell lymphoma[J]. Curr Opin Oncol, 2012, 24(5):480-486. doi: 10.1097/CCO.0b013e3283556142 URL
[8]	Cheson BD. Role of functional imaging in the management of lymphoma[J]. J Clin Oncol, 2011, 29(14):1844-1854. doi: 10.1200/JCO.2010.32.5225 pmid: 21482982
[9]	Yi JH, Kim SJ, Choi JY, et al. ¹⁸F-FDG uptake and its clinical relevance in primary gastric lymphoma[J]. Hematol Oncol, 2010, 28(2):57-61.
[10]	Chang Y, Fu X, Sun Z, et al. Utility of baseline, interim and end-of-treatment ¹⁸F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase[J]. Sci Rep, 2017, 7:41057. doi: 10.1038/srep41057 pmid: 28117395
[11]	Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol, 2014, 32(27):3048-3058. pmid: 25113771
[12]	Suh C, Kang YK, Roh JL, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extra-nodal natural killer/T-cell lymphomas of the head and neck[J]. J Nucl Med, 2008, 49(11):1783-1789. doi: 10.2967/jnumed.108.053355 URL
[13]	Cottereau AS, Buvat I, Kanoun S, et al. Is there an optimal method for measuring baseline metabolic tumor vo-lume in diffuse large B cell lymphoma?[J]. Eur J Nucl Med Mol Imaging, 2018, 45(8):1463-1464. doi: 10.1007/s00259-018-4005-4 URL
[14]	Kim CY, Hong CM, Kim DH, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2013, 40(9):1321-1329. doi: 10.1007/s00259-013-2443-6 URL
[15]	Lin N, Song Y, Zheng W, et al. A prospective phase Ⅱ study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type[J]. J Hematol Oncol, 2013, 6:44. doi: 10.1186/1756-8722-6-44 URL
[16]	Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relap-sing extranodal NK/T-cell lymphoma, a phase 2 study[J]. Blood, 2011, 117(6):1834-1839. doi: 10.1182/blood-2010-09-307454 pmid: 21123825
[17]	Xu PP, Xiong J, Cheng S, et al. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type[J]. EBioMedicine, 2017, 25:41-49. doi: 10.1016/j.ebiom.2017.10.011 URL

项目	SUVmax	MTV（cm³）	TLG（×10³）
最佳阈值	8.05	16.97	74.70
灵敏度（%）	80.0	100	100
特异度（%）	27.3	77.3	54.5
曲线下面积	0.309	0.891	0.727
P值	0.190	0.007	0.119
95% CI	9.7~13.7	12.1~19.6	67.7~118.4

¹⁸F-FDG PET/CT代谢参数在NK/T细胞淋巴瘤预后价值的评估

Prognostic value of ¹⁸F-FDG PET/CT metabolic parameters in NK/T cell lymphoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 17

相关文章 1

编辑推荐

Metrics

本文评价